Neffy NOW AVAILABLE
For the treatment of type I allergic reactions1
neffy® is the first and only FDA-approved needle-free way to administer epinephrine.1,2 It's a nasal spray that is now approved for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg (66 lb) or greater.
New from the American College of Allergy, Asthma and Immunology: Prior Authorization Appeal Letter Generator
Learn moreABOUT
INTRODUCING neffy
Innovative intranasal delivery of epinephrine at the first sign of a severe allergic reaction
For patients with a severe allergic reaction, neffy is the first and only FDA-approved needle-free way to administer epinephrine1,2
- Rapid effects on blood pressure and heart rate (key PD surrogate markers) within 1 minute, delivering changes comparable to IM injection products1,3,4*
- Well tolerated in clinical trials1
- Designed to be small, easy to carry, and easy to use5,6
DOSING AND ADMINISTRATION
IN ACCORDANCE WITH ITS INSTRUCTIONS FOR USE,
Patients insert and press to administer neffy
Preparing for administration of neffy:
- Patients should be advised on when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required1
- Each single-use neffy spray device delivers an intranasal dose containing
2 mg of epinephrine. Patients should not prime or attempt to reuse neffy for more than one administration1 - It is recommended that patients are prescribed and have immediate access to 2 neffy devices at all times, so that they are always prepared with a primary and a backup1
- Single-use neffy can be administered while the patient is in any position (ie, supine, semi-supine, standing, or sitting)1
- Remove neffy spray device from packaging before use8
During administration of neffy1:
Patients should use the right hand to administer neffy to the right nostril and use the left hand to administer neffy to the left nostril.
To administer neffy, patients or caregivers should:
- HOLD the device with your thumb on the bottom of the plunger and a finger on either side of the nozzle
- INSERT the nozzle of the nasal spray device fully into one nostril until their fingers touch the nose; they must not angle the nasal spray to the inside septum or outer wall of the nose, as some medication may be lost
- PRESS the plunger firmly to activate. Do not sniff during or after administration
Following administration of neffy1:
- In the absence of clinical improvement or if symptoms worsen after the initial treatment, a second dose of neffy may be administered in the same nostril with a second nasal spray starting 5 minutes after the first dose
- More than 2 sequential doses of epinephrine should be administered under direct medical supervision
In studies designed to evaluate success of administration, 100% of adults and pediatric participants (N=16; N=42) were able to administer neffy without error5,6
PROGRAMS & RESOURCES
Streamlined neffy prescription fulfillment with BlinkRx
Follow these steps:
- 1. In your EMR, ePrescribe neffy to BlinkRx US, Boise, Idaho
Phone: 1-833-914-4805
Fax: 1-866-585-4631 - 2.BlinkRx contacts your patient with a confidential text message and analyzes your patient’s insurance. BlinkRx will apply available savings offers to eligible patients, including the neffy commercial co-pay savings*
- 3. Your patient’s prescription is delivered through free home delivery. Payment is collected over the phone or through the patient’s mobile platform
BlinkRx supports neffy with:
- Convenient application of savings
- Free shipping
- Smart refill reminders
- Support processing formulary exceptions/prior authorization requests
*Terms and conditions apply.
EMR, electronic medical record.
Help your patients access neffy
If you are having trouble getting neffy approved for your patients with type 1 allergic reactions, the American College of Allergy, Asthma and Immunology’s Prior Authorization (PA) Appeal Letter Generator may be able to help. This easy-to-use tool will create an evidence-based PA appeal letter, customized for your patient, in a few simple steps.
For patients with commercial insurance, pricing may be as low as
$25 per prescription*
Support services designed for your patients
With neffyconnect, your patients can receive access support, financial assistance, and education
ACCESS: Helps patients get the neffy they need, even if insurance barriers arise
- Patients can have their neffy filled by BlinkRx or a pharmacy of their choice
- BlinkRx can help with formulary exceptions/prior authorizations and appeals
ASSISTANCE: Helps patients afford their neffy
Co-Pay Savings Program:
- Eligible, commercially insured patients may pay as little as $25 per prescription*
- Eligible patients will be able to access the universal co-pay card in September
ARS Patient Assistance Program:
- ARS provides medically necessary neffy free of charge to qualifying applicants through its Patient Assistance Program. Restrictions apply
EDUCATION: Dedicated support staff, resources, and tools for your patients
- Patients can connect with case managers and receive emails from neffyconnect with helpful resources and tools
Inform your patients about the comprehensive support, resources, and financial assistance they may receive by signing up for neffyconnect
For assistance prescribing neffy through BlinkRx, call BlinkRx at 1-833-914-4805 or visit blinkrx.com
Get your neffy demonstration kit today
Help improve the patient experience with neffy demonstration devices*
Demonstration devices can be a valuable tool for ensuring patient education and compliance. neffy demonstration devices are delivered in a compact box that’s easy to store. Each kit includes 2 spring-loaded reusable devices and 10 air-filled disposable devices, along with supportive educational materials. neffy demonstration devices provide the perfect opportunity for patients, caregivers, school nurses, and pharmacists to become familiar with administering neffy and gain confidence in its ease of use during an emergency situation.
*Demonstration devices are for demonstration and training only. Does not contain active ingredient.
Looking for neffy resources?
Download our neffy Introduction & How to Use Presentation to learn more
DownloadCONNECT WITH US
Learn more about neffy—for your patients with type I allergic reactions
Request information by checking the appropriate box(es) below:
References:
- neffy [prescribing information]. San Diego, CA: ARS Pharmaceuticals Operations, Inc.
- Data on file. neffy press release. ARS Pharmaceuticals. 2024.
- Data on file. CSR EPI 15. ARS Pharmaceuticals Operations, Inc. 2023.
- Data on file. CSR EPI 16. ARS Pharmaceuticals Operations, Inc. 2023.
- Casale TB, Lockey R, Portnoy J, et al. Pharmacokinetics of self-administration of ARS-1 (neffy® Nasal Spray) 2.0 mg versus manual intramuscular (IM) epinephrine 0.3 mg by health care provider (HCP). Presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting; February 24, 2023: San Antonio, TX.
- Data on file. Human Factors Study. ARS Pharmaceuticals Operations, Inc. 2024.
- Ellis AK, Casale TB, Kaliner M, et al. Development of neffy, an epinephrine nasal spray, for severe allergic reactions. Pharmaceutics. 2024; 16(6):811. doi.org/10.3390/pharmaceutics16060811
- Instructions for use. ARS Pharmaceuticals Operations, Inc. 2024.